View Cart  

FDA Advisory Panel Recommends Aegerion’s Lomitapide to Treat HoFH

A A
Despite liver toxicity concerns, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 13–2 to recommend approval of Aegerion Pharmaceuticals’ lomitapide.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00